Exhibit 99.1
JOHNSON & JOHNSON
REPORTED SALES vs. PRIOR PERIOD
(Unaudited, Dollars in Millions)
First Quarter % Change
2007 2006 Reported Operational* Currency
CONSUMER SEGMENT (1)
OTC/Nutritional
US $ 655 445 47.3% 47.3 -
Intl 602 208 188.8 182.3 6.5
WW 1,257 653 92.5 90.4 2.1
Skin Care
US 357 318 12.4 12.4 -
Intl 407 341 19.2 13.1 6.1
WW 764 659 16.0 12.8 3.2
Baby & Kids Care
US 109 103 5.5 5.5 -
Intl 338 303 11.5 6.8 4.7
WW 447 406 9.9 6.4 3.5
Women's Health
US 163 148 10.3 10.3 -
Intl 258 251 2.8 (2.3) 5.1
WW 421 399 5.6 2.5 3.1
Oral Care
US 203 55 270.2 270.2 -
Intl 156 38 306.0 301.8 4.2
WW 359 93 285.0 283.3 1.7
Other
US 142 81 74.6 74.6 -
Intl 106 64 65.9 61.1 4.8
WW 248 145 71.4 69.3 2.1
Total Consumer Segment
US 1,629 1,150 41.7 41.7 -
Intl 1,867 1,205 54.9 49.4 5.5
WW $3,496 2,355 48.5% 45.7 2.8
(1) 2007 includes sales from acquisition of PCH
PHARMACEUTICAL SEGMENT
Anti-Psychotics (2)
US $ 710 585 21.4% 21.4 -
Intl 468 433 7.9 1.9 6.0
WW 1,178 1,018 15.7 13.2 2.5
EPREX(R)/PROCRIT(R)
US 530 527 .5 .5 -
Intl 287 259 10.9 3.5 7.4
WW 817 786 3.9 1.5 2.4
REMICADE(R) (3)
US 731 681 7.4 7.4 -
WW 731 681 7.4 7.4 -
TOPAMAX(R)
US 501 373 34.4 34.4 -
Intl 109 98 11.4 4.9 6.5
WW 610 471 29.7 28.4 1.3
LEVAQUIN(R)/FLOXIN(R)
US 460 393 17.0 17.0 -
Intl 15 10 49.7 53.4 (3.7)
WW 475 403 17.8 17.9 (.1)
ACIPHEX(R)/PARIET(R)
US 159 146 9.1 9.1 -
Intl 177 160 10.4 4.6 5.8
WW 336 306 9.8 6.8 3.0
DURAGESIC(R)/Fentanyl Transdermal
US 116 110 4.8 4.8 -
Intl 187 215 (12.8) (17.9) 5.1
WW 303 325 (6.8) (10.2) 3.4
CONCERTA(R)
US 200 193 3.4 3.4 -
Intl 52 42 25.3 17.9 7.4
WW 252 235 7.3 6.0 1.3
Hormonal Contraceptives
US 174 198 (12.0) (12.0) -
Intl 63 56 13.0 8.1 4.9
WW 237 254 (6.5) (7.6) 1.1
Other
US 453 495 (8.4) (8.4) -
Intl 829 652 27.1 20.5 6.6
WW 1,282 1,147 11.8 8.7 3.1
Total Pharmaceutical Segment
US 4,034 3,701 9.0 9.0 -
Intl 2,187 1,925 13.6 7.7 5.9
WW $6,221 5,626 10.6% 8.6 2.0
(2) Includes RISPERDAL(R), RISPERDAL CONSTA(R) & INVEGA(R)
(3) US REMICADE(R) sales includes International Distributors of $131
Q1 2007 & $115 Q1 2006
MEDICAL DEVICES AND DIAGNOSTICS
DEPUY(R)
US $ 678 644 5.3% 5.3 -
Intl 479 395 21.1 13.6 7.5
WW 1,157 1,039 11.3 8.4 2.9
CORDIS(R)
US 424 530 (20.1) (20.1) -
Intl 504 545 (7.4) (10.7) 3.3
WW 928 1,075 (13.6) (15.3) 1.7
ETHICON ENDO-SURGERY(R)
US 417 380 9.8 9.8 -
Intl 474 414 14.6 9.0 5.6
WW 891 794 12.3 9.4 2.9
ETHICON(R)
US 344 296 16.4 16.4 -
Intl 526 478 9.9 4.2 5.7
WW 870 774 12.4 8.8 3.6
LIFESCAN(R)
US 292 288 1.5 1.5 -
Intl 257 216 18.7 12.0 6.7
WW 549 504 8.9 6.0 2.9
Total Vision Care
US 195 172 13.5 13.5 -
Intl 318 269 18.2 16.3 1.9
WW 513 441 16.4 15.2 1.2
ORTHO-CLINICAL DIAGNOSTICS(R)
US 219 199 10.2 10.2 -
Intl 174 171 1.5 (3.1) 4.6
WW 393 370 6.2 4.1 2.1
Other
US 15 11 35.6 35.6 -
Intl 4 3 26.1 19.2 6.9
WW 19 14 38.6 37.8 .8
Total MD&D Segment
US 2,584 2,520 2.5 2.5 -
Intl 2,736 2,491 9.8 4.7 5.1
WW $5,320 5,011 6.2% 3.7 2.5
*Operational growth excludes the effect of currency